Lumineyes™ Clinical Data: Nine Years of Longitudinal Clinical Observations

1. Clinical Cohort and Data Provenance

The present dataset derives from routine ophthalmic care delivered through the Lumineyes™ program during 2017–2026, a nine-year period of contemporary clinical application. The program was developed by ophthalmologist Mustafa Mete, MD. Initial method-development work began before this observation period; the present clinical results, however, refer to the nine-year cohort.

Clinical information was accumulated through office records, treatment-session documentation, examinations, serial photographs, pressure measurements, and other ophthalmic assessments when performed. The records span treatment planning, postoperative evaluation, successive treatment episodes, and follow-up visits. Clinical events are described in the units originally reported, with patient-level, eye-level, and treatment-session measures distinguished.

Units of observation

The clinical archive records data at several complementary levels. Patient-level findings include age, medical history, selection criteria, and participant-reported responses. Eye-level findings include baseline ocular measurements, pigment phenotype, IOP, corneal status, and anatomical findings. Session-level data describe individual treatment exposures, cumulative exposure history, intervals, and immediate responses. Visit-level observations describe recovery and longitudinal evolution.

Clinical record architecture and chronological interpretation

The longitudinal record contains different categories of information that serve complementary purposes. Procedure sheets can establish the date and extent of a laser exposure, whereas a postoperative visit provides a separate record of ocular status at a particular time. Serial images may describe pigmentation but do not automatically supply contemporaneous tonometry, endothelial measurements, or inflammatory grading. Analytical linkage among these sources therefore depends on the patient, the eye and the examination date. This approach supports direct reconstruction of individual treatment courses while preserving the original sequence of clinical events.

For clinical reporting, an episode that arises shortly after one treatment session is distinguished from a finding noted during a later consultation, a repeatedly observed condition, and a new diagnosis established after the last recorded exposure. This temporal organization is valuable for adverse-event characterization and for evaluation of progressive pigment changes across several stages of treatment.

2. Clinical Methodology and Protocol Development

The Lumineyes™ approach is a physician-developed, non-incisional procedure directed toward modulation of anterior stromal iris pigmentation. Its clinical model comprises patient selection, anatomical assessment, conservative and staged laser exposure, response-dependent progression, postoperative management, and longitudinal ophthalmic surveillance.

Pre-treatment assessment

The clinical selection process considers ocular history, baseline visual function, anterior-segment findings, iris pigment characteristics, IOP, angle anatomy and relevant contraindications. Systemic disease, prior ocular intervention, inflammatory status, medication exposure, and treatment adherence are considered in clinical decision-making. Each eye is evaluated individually rather than assigned a fixed number of treatment sessions independent of clinical response.

Staged exposure and interval-based decisions

Laser treatment is performed in sequential stages with clinical reassessment between treatment blocks. The evolving protocol incorporates targeted pigment interaction and visual assessment of pigment dispersion, tissue response, and subsequent clearance. Immediate treatment findings and later changes in iris appearance are interpreted on distinct timescales. The approach to early IOP surveillance, postoperative inflammatory monitoring, treatment intervals, and continuation decisions has been refined through the clinical program.

Methodological continuity and later formalization

Scientific terminology developed from this clinical experience, including selective stromal melanin modulation (SSMM), the L-SAFE clinical state architecture, and the L-OAT iris phenotype framework, provides a structured description of procedural targets and measurement priorities. These frameworks formalize clinical concepts and support reproducible future research; the historical patient record remains defined by the assessments actually performed at each visit.

Protocol refinements across the observation period

The contemporary nine-year period includes progressive refinements in the technical and clinical delivery of the treatment. In analytical work, procedure-era designation permits clinically meaningful grouping of exposure practices, monitoring intervals, and evolving treatment methods without requiring historical visits to be recoded as modern procedures. This also allows later outcome analyses to compare clinical patterns within internally defined treatment generations rather than presuming complete technical uniformity over nine years.

The overall clinical series should consequently be read as the longitudinal experience of one developing clinical program. When individual data extraction is complete, subgroup analyses can examine whether observed findings vary by treatment generation, baseline pigment characteristics, exposure history, and the time interval between sessions.

3. Nine-Year Clinical Outcomes

The following table summarizes the principal clinical observations reported for the contemporary Lumineyes™ cohort. Results are grouped by domain and timing to distinguish pigment response, transient postoperative findings, and observations during later follow-up.

4. Pigment Response and Iris Phenotype Evolution

The nine-year clinical archive reports a 97.4% clinic-assessed pigment-response endpoint. This observation characterizes response during treatment, while final iris phenotype is a longitudinal outcome that can continue to evolve after the immediate laser exposure period. Variation in stromal pigment density, iris architecture, pigmentation grade, treatment intensity, number of sessions, and recovery interval can influence the observed course.

Clinical assessment distinguishes visible pigment dispersion at the treatment site, the subsequent appearance of the iris, and the stabilization of a later phenotype. These observations have shaped the staged Lumineyes™ approach and the development of a more formal language for phenotype grading and objective imaging.

Temporal structure of response

The immediate optical and particulate response occurs at the time of laser interaction. Subsequent anterior-chamber and local stromal observations evolve during the recovery period. Visible pigment changes may continue after treatment, and clinical evaluation is therefore longitudinal rather than limited to a single postoperative photograph. The temporal perspective is developed further in the associated P-CLEAR and Temporal Response Architecture research programs.

Quantitative phenotype endpoints

Future image-based analyses will use serial standardized iris photography and, where available, anterior-segment imaging to evaluate spatial pigment change. Potential variables include regional pigmentation, heterogeneity, colorimetric change, anatomical visibility, response by starting grade, and the relationship between cumulative exposure and subsequent phenotype. The L-OAT framework provides an architecture for this prospective measurement approach.

Visual response and photographic measurement

Serial iris photographs are especially useful for illustrating changes that develop over weeks and months. Consistent illumination, camera optics, distance, pupil size, white balance, and image processing are essential when photography is used for numerical color comparison. Photographs obtained primarily for routine clinical documentation may remain valuable for descriptive review, whereas calibrated prospective imaging is the preferred basis for formal quantitative phenotype measurements. Clinical grading and digital measurement should be retained as related but distinct endpoints.

Within the proposed LIPS-based analysis, an eye's baseline stromal pigmentation grade can be considered together with its subsequent response course. L-OAT adds a framework for recording regional phenotype and structural context, allowing a more informative description than a single whole-iris color label. Long-term phenotype studies will also report the time interval since the most recent session, because a newly treated eye and an eye observed many months later represent different states of the response process.

5. Intraocular Pressure: Early Events and Longitudinal Trajectories

Intraocular pressure assessment is incorporated into Lumineyes™ screening, postoperative review, and longitudinal ophthalmic evaluation. The clinical archive identifies approximately 15 patients who experienced transient early IOP elevation during the program. These episodes were treated medically according to the clinical circumstances. The available archive reports no documented chronic or progressive IOP elevation attributable to the treatment program.

An important longitudinal observation is the presence of lower IOP measurements in selected patients during later follow-up. These changes warrant eye-specific paired analysis, with explicit treatment dates, baseline tonometry, medication use, examination intervals, and successive measurements. Early postoperative pressure excursions and subsequent IOP trajectories represent distinct temporal patterns and are presented separately.

Clinical interpretation of early and late IOP

Early clinical review emphasizes detection and management of a pressure elevation within the postoperative recovery interval. Longer-term observation considers individual baseline values, IOP measured without or with treatment, ocular examination findings, and the trajectory across multiple visits. The clinical protocol addresses these phases within its own examination and management framework; the present report focuses on the recorded clinical outcomes.

6. Corneal and Anterior-Segment Findings

The reported corneal response profile includes transient corneal edema and Descemet folds in approximately 3% of treated eyes. The archived clinical description characterizes these events as temporary findings associated with recovery. Additional postoperative observations include mild iridocyclitis and episodes of transient fibrinous or pupillary membrane response. The clinical record reports no posterior synechiae.

Corneal clarity, anterior-chamber response, pupil configuration, and inflammation were considered in subsequent treatment decisions. Event timing and resolution are important clinical dimensions: an immediate transient corneal response is distinct from a persistent corneal structural change, just as a short-lived inflammatory membrane is distinct from permanent synechial change.

Endothelial assessment as a defined research endpoint

Quantitative evaluation of corneal endothelial reserve is a high-priority extension of the clinical program, particularly in individuals who have undergone many treatment sessions or long observation periods. Planned investigation will use standardized specular microscopy and paired measurements where available, including endothelial cell density, coefficient of variation in cell area, percentage of hexagonal cells, and relevant accompanying anterior-segment measures. The methodological basis for such analysis is described in the ophthalmic specular-microscopy literature.^[9]

Clinical event chronology and recovery

Postoperative events are most informative when their onset, highest recorded severity, intervention, and resolution are considered as a continuous clinical episode. Early pressure changes, corneal edema, and anterior-segment inflammation do not necessarily share the same time course. Their clinical records can be organized into an onset date, a period of active observation or management, and a resolution assessment. This permits episodes that resolve promptly to be characterized accurately and separates them from conditions that recur or remain present at later visits.

In the formal study, the event record can also describe laterality, whether an event followed a particular treatment session, its clinical consequences, and the interval to the next exposure. This organization preserves the meaningful clinical detail behind a numerical summary and is valuable in a sequential-treatment protocol.

7. Visual Function, Retina, and Optic Nerve

Available follow-up records contain no documented treatment-associated permanent vision loss. Clinical assessment of visual function is considered alongside anterior-segment findings and, when performed, retinal and optic-nerve examination or imaging.

A future formal outcome dataset can stratify best-corrected visual acuity, refractive status, ocular comorbidity, optic-nerve findings, and indicated posterior-segment imaging. Recording these variables together helps distinguish procedure-associated changes from pre-existing ocular characteristics and unrelated events during follow-up.

The research literature includes reports of posterior-segment findings following other cosmetic iris laser procedures; these cases provide context for clinical surveillance and are not part of the Lumineyes™ patient series.^[5,7] The relevant scientific comparison is between clearly described treatment protocols and their respective measured outcomes, rather than a single pooled label for all laser iris depigmentation methods.

8. Longitudinal Follow-Up and Age-Related Clinical Context

Longitudinal assessment is an essential feature of the nine-year program. Selected records in the current compiled summary contain observations through 96 months. Additional clinical history includes a patient who began treatment at age 71 and is now 80, illustrating the difference between age at initial treatment, elapsed calendar time, and individually documented follow-up examinations.

Serial assessment allows investigation of treatment response persistence, iris phenotype evolution, pressure behavior, corneal findings, and ocular health during long time horizons. Because patients entered the program at different dates, the number of eyes contributing observations at each follow-up horizon varies. The formal retrospective study will therefore report the availability of examinations at defined postoperative intervals.

Longitudinal observation by treatment age and chronological age

Two time scales operate simultaneously in this cohort. Treatment time begins at an individual eye's first exposure; chronological age continues from the patient's birth date. In patients who return after several years, a later examination therefore reflects both elapsed time since treatment and age-related ocular change. This distinction becomes particularly relevant for corneal endothelium, lens status, IOP, and other anterior-segment findings that may evolve with age independently of treatment.

The oldest patient was 71 years old at treatment initiation and is 80 in 2026. For reporting demographic characteristics, the correct treatment-age upper bound is 71 years. For long-term clinical follow-up, the patient's current age and the interval since treatment provide additional clinical context; neither replaces the date of the most recent documented examination.

9. Cumulative Treatment Exposure and Clinical Response

The Lumineyes™ program uses a staged treatment model in which total session number varies by baseline pigmentation and the observed course. A single fixed exposure schedule would not capture the range of clinical trajectories represented in the archive. Treatment intervals, response grade, session history, and anatomical findings are therefore relevant descriptors of the procedure.

For scientific analysis, cumulative exposure can be expressed as number of sessions per eye, treatment-course duration, intervals between exposures, protocol generation, and documented energy-delivery characteristics where recorded. Clinically important stratifications include eyes with low cumulative exposure, repeated staged treatment, high cumulative exposure, and multi-year treatment histories.

High-exposure individuals are particularly informative for long-term corneal endothelial examination and structured anatomical review. Their examination profiles provide focused opportunities for objective imaging and direct comparison with earlier measurements where available.

10. Patient Selection and Clinical Decision-Making

Appropriate patient selection is integral to the Lumineyes™ treatment system. Eligibility decisions address ocular disease, inflammatory history, ocular anatomy, baseline IOP, systemic conditions, prior procedures, adherence, and expectations. The clinical process incorporates both the suitability of an individual eye and the ability to complete staged ophthalmic follow-up.

Clinical decisions during a treatment course are likewise individualized. Progression is based on the eye's response at subsequent assessments; the program integrates criteria for additional examination, deferral, treatment interruption, or discontinuation when indicated. Selection and follow-up represent parts of the procedural methodology that should be captured as variables in the formal research dataset.

Clinical selection and treatment discontinuation as research variables

Eligibility decisions, exclusions, deferrals and incomplete treatment courses provide information about the clinical population to whom the observed outcomes apply. An observational clinical cohort is the result of both treatment and patient selection. A complete formal dataset can therefore record the clinical reason for acceptance, non-initiation, or later discontinuation, separating anatomical concerns from adherence, treatment expectations, and medical contraindications where documented.

This information is important when interpreting efficacy outcomes, since patients who complete a lengthy staged course may differ from those who stop early. It also supports patient-centered reporting of treatment burden, number of visits, and duration of the clinical course instead of interpreting the visible final phenotype as the sole outcome of treatment.

11. Relationship to Published Ophthalmic Literature

The literature on cosmetic alteration of iris color encompasses different procedures and different biological targets, including laser-based approaches and surgical alternatives. These interventions should be described with enough technical and clinical detail to support meaningful comparison.^[1,2,10]

A published 2021 series of 1,176 eyes undergoing photoablative cosmetic iridoplasty provides an example of a separately described laser protocol and its own clinical outcomes.^[1] Other publications report pressure-related and posterior-segment adverse outcomes after cosmetic iris laser procedures, often with incomplete disclosure of original treatment parameters.^[3–7] The Lumineyes™ program is assessed here from its own clinical observations and its own staged, response-guided clinical methodology.

12. Mechanistic Interpretation and the Lumineyes™ Scientific Framework

Selective stromal melanin modulation (SSMM) describes the intended target and clinical logic of the contemporary method: preferential interaction with iris stromal pigment within a staged ophthalmic protocol. The observed local response is interpreted in relation to pigment distribution, optical delivery, anatomical structure, cumulative exposure and elapsed recovery time.

Selective photothermolysis provides one foundational description of chromophore-dependent pulsed-light interaction, while the biological context of ocular melanin involves absorption, photobiology and cellular relationships within the iris.^[11,12] In the Lumineyes™ research architecture, the clinical observations motivate measurement-oriented studies of pigment dynamics and longer-term tissue response.

Interpreting immediate response and delayed change

The clinical distinction between pigment interaction at exposure and the later visible iris phenotype is central to the program. The temporal and compartment-specific approach avoids treating pigment dispersion, subsequent clearance, and final appearance as synonymous endpoints. Prospective measurement designs can examine these stages with standardized photographs, relevant imaging, pressure measurements, and validated analytical methods.

13. Statistical Framework for the Retrospective Clinical Study

The nine-year archive provides the clinical source for a formal patient- and eye-level analytical dataset. A dedicated retrospective research protocol will define the eligibility window, primary endpoints, clinically relevant subgroups, and longitudinal time points. Data extraction will preserve original clinical measurements, treatment dates and eye laterality, with patient identifiers replaced by coded research keys.

Primary and secondary analyses

Primary descriptive analyses can report treatment response, postoperative events and longitudinal IOP observations. Secondary analyses can examine response by baseline pigmentation, cumulative treatment exposure, protocol era, and follow-up duration. Where both eyes contribute outcomes, statistical methods will account for within-patient correlation. Longitudinal continuous variables, including IOP and quantitative endothelial measures when available, can be evaluated using paired and repeated-measures approaches appropriate to the observed visit structure.

In the formal manuscript, a concise limitations paragraph will address the retrospective clinical setting, variation in follow-up availability, and completeness of historical measurements. This standard methodological disclosure is part of the research design rather than a qualification repeated throughout the clinical results.

Endpoint definitions and statistical sensitivity

Precise outcome denominators are assigned at the level relevant to each result. Patient-level counts are appropriate for participant characteristics; eye-level denominators are used for pressure, corneal, iris and visual outcomes; session-level exposures describe immediate post-laser observations. Serial examinations of one eye are repeated observations rather than independent patients. This structure determines the statistical approach and allows confidence intervals to reflect the actual number of independent clinical units contributing information.

For continuous outcomes, the primary analysis may estimate within-eye change from documented baseline, supplemented by longitudinal mixed-effects modeling when visit availability supports it. Event summaries can report count, severity and follow-up horizon. Prespecified sensitivity analyses can compare complete records with the broader extracted cohort, examine different clinically relevant follow-up intervals, and evaluate the influence of treatment-era stratification. Missingness should be summarized once in the methodological report, while numerical findings remain presented in their own results tables.

14. Research Program and Next-Stage Clinical Evidence

Formal conversion of the clinical archive into a study dataset can proceed through focused source-record extraction. The first workstream defines a stable cohort and standardized variables for patient age at treatment, eye laterality, treatment course, IOP, events, visual outcomes and follow-up dates. A parallel workstream identifies long-follow-up cases and patients with high cumulative treatment exposure for dedicated anterior-segment examination.

Long-term corneal endothelial investigation

One priority is a dedicated clinical study of endothelial cell density and morphology in individuals representing different cumulative exposure categories. Standardized specular microscopy with suitable paired historical values, when available, can quantify long-term endothelial findings and characterize the heterogeneity between individual treatment histories.

Longitudinal IOP investigation

Another priority is reconstruction of eye-specific IOP trajectories with accompanying medication, visit and treatment histories. This analysis can describe the distinct time courses of transient early postoperative elevations and later measured values, including patients in whom lower IOP was recorded during follow-up.

Phenotype evolution and image-based measurement

Standardized photographs and anterior-segment imaging can support structured analysis of visible iris phenotype over time, particularly when paired with original pigment grade and exposure history. The LIPS and L-OAT frameworks provide a consistent vocabulary for research measurement and clinical characterization.

Selection of documented long-follow-up cases

In addition to the cohort analysis, representative clinical histories can illustrate distinct longitudinal patterns: sustained pigment evolution, stable later phenotype, early postoperative recovery, long-term IOP measurements, and high cumulative session exposure. For scientific reporting, cases should be chosen using defined criteria—for example, elapsed time since treatment or availability of paired examinations—rather than the visual appeal of a photograph. A case profile ideally combines original treatment age, eye laterality, exposure history, baseline examination, serial clinical assessments, and the timing of the most recent objective measurement.

Such case profiles complement population-level descriptive results by showing the individual trajectories behind aggregate endpoints. High-session histories are also an efficient starting point for standardized endothelial investigation, particularly when earlier clinical records can be linked with new objective imaging.

15. Discussion

The principal contribution of the Lumineyes™ archive is the combination of a substantial procedure-specific clinical experience, a staged treatment methodology, and records extending over a nine-year contemporary practice period. The accumulated clinical observations provide information on pigment response, treatment progression, anterior-segment recovery, early IOP events, and selected long-term ocular outcomes.

Reported pigment response is high within the clinic-assessed endpoint, and available records have not documented chronic/progressive IOP elevation or treatment-associated permanent vision loss. Transient responses—early pressure elevation, corneal edema, mild inflammation, and occasional fibrinous change—are identifiable elements of the clinical postoperative profile. Long-follow-up cases and individuals with numerous treatment exposures are scientifically useful for objective assessment of cumulative ocular outcomes.

The archive also illustrates the importance of treating laser iris depigmentation as a collection of technically distinct methods rather than one interchangeable intervention. Comparative scientific interpretation requires anatomical targeting, optical delivery, exposure pattern, patient selection, and postoperative management to be specified for each method. The contemporary Lumineyes™ methodology integrates those elements into a coherent clinical approach.

For the planned original research manuscript, the key methodological tasks are precise patient- and eye-level denominators, documented outcome definitions, follow-up distribution, original clinical measurements, and prespecified analyses. Those elements will convert the established clinical observations into reproducible statistical results while retaining their nine-year clinical context.

16. Conclusion

The Lumineyes™ nine-year clinical archive (2017–2026) encompasses approximately 1,500 patients, more than 3,000 treated eyes, and a treated age range of 18–71 years. Selected compiled clinical follow-up extends to 96 months. The archive reports a 97.4% clinic-assessed pigment response, medically managed transient early pressure elevation in approximately 15 patients, transient corneal edema in approximately 3% of treated eyes, and additional short-lived inflammatory responses. No chronic or progressive IOP elevation or treatment-associated permanent vision loss has been documented in the available clinical records.

These longitudinal observations represent the clinical foundation of the Lumineyes™ SSMM program and an extensive basis for formal retrospective outcome analysis, objective corneal endothelial assessment, standardized iris phenotyping and sustained ophthalmic follow-up research.

References

1. Ruiz PG. Photoablative cosmetic iridoplasty: effective, safe, and predictable-eye color change in 1176 eyes. Int Ophthalmol. 2021;41(4):1381-1393. doi: 10.1007/s10792-021-01693-5. PMID:33484383.
2. D'Oria F, Abu-Mustafa SK, Alio JL. Cosmetic Change of the Apparent Color of the Eye: A Review on Surgical Alternatives, Outcomes and Complications. Ophthalmol Ther. 2022;11(2):465-477. doi: 10.1007/s40123-022-00458-2. PMID:35061240.
3. Ong AY, Ching-A-Sue G, Krilis M, Guirao-Navarro MC, Hornby S, Jutley G. Refractory iatrogenic pigmentary glaucoma secondary to cosmetic laser treatment: a case report. Eur J Ophthalmol. 2023;33(2):NP1-NP4. doi: 10.1177/11206721211050338. PMID:34623172.
4. Swampillai AJ, Sherman T, Garg A, Tan IJ, Lim KS. Secondary pigmentary glaucoma following cosmetic laser treatment to alter iris colour. Cont Lens Anterior Eye. 2023;46(2):101754. doi: 10.1016/j.clae.2022.101754. PMID:36175318.
5. Liu J, Korban S, Moster MR, Rhéaume MA, Wang Q. Bilateral severe iatrogenic pigmentary glaucoma following laser treatment for cosmetic iris color change. Am J Ophthalmol Case Rep. 2023;32:101927. doi: 10.1016/j.ajoc.2023.101927. PMID:37771388.
6. Jaber W, Nemet M, Waisbourd M. Laser Iris Depigmentation Resulting in Markedly Elevated Intraocular Pressure and Herpes Simplex Keratitis with Corneal Scarring: Case Report. Case Rep Ophthalmol. 2026;17(1):312-317. doi: 10.1159/000551226. PMID:41982480.
7. Flores-Márquez A, Moreno-Gutiérrez JA, Chinchurreta-Capote A, García-Martín F, Rocha-de-Lossada C. Laser-induced maculopathy after iris depigmentation cosmetic treatment. Can J Ophthalmol. 2023;58(1):e29-e31. doi: 10.1016/j.jcjo.2022.05.012. PMID:35809624.
8. Scuderi G, Contestabile MT, Scuderi L, Librando A, Fenicia V, Rahimi S. Pigment dispersion syndrome and pigmentary glaucoma: a review and update. Int Ophthalmol. 2019;39(7):1651-1662. doi: 10.1007/s10792-018-0938-7. PMID:29721842.
9. McCarey BE, Edelhauser HF, Lynn MJ. Review of corneal endothelial specular microscopy for FDA clinical trials of refractive procedures, surgical devices, and new intraocular drugs and solutions. Cornea. 2008;27(1):1-16. doi: 10.1097/ICO.0b013e31815892da. PMID:18245960.
10. D'Oria F, Alio JL. Surgical Techniques for Cosmetic Eye Color Change: A Narrative Review. Ophthalmol Ther. 2025;14(8):1685-1694. doi: 10.1007/s40123-025-01177-0. PMID:40483374.
11. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220(4596):524-527. doi: 10.1126/science.6836297. PMID:6836297.
12. Hu DN, Simon JD, Sarna T. Role of ocular melanin in ophthalmic physiology and pathology. Photochem Photobiol. 2008;84(3):639-644. doi: 10.1111/j.1751-1097.2008.00316.x. PMID:18346089.